114 related articles for article (PubMed ID: 16495473)
1. Human REV1 modulates the cytotoxicity and mutagenicity of cisplatin in human ovarian carcinoma cells.
Lin X; Okuda T; Trang J; Howell SB
Mol Pharmacol; 2006 May; 69(5):1748-54. PubMed ID: 16495473
[TBL] [Abstract][Full Text] [Related]
2. Suppression of hREV1 expression reduces the rate at which human ovarian carcinoma cells acquire resistance to cisplatin.
Okuda T; Lin X; Trang J; Howell SB
Mol Pharmacol; 2005 Jun; 67(6):1852-60. PubMed ID: 15758147
[TBL] [Abstract][Full Text] [Related]
3. DNA polymerase zeta accounts for the reduced cytotoxicity and enhanced mutagenicity of cisplatin in human colon carcinoma cells that have lost DNA mismatch repair.
Lin X; Trang J; Okuda T; Howell SB
Clin Cancer Res; 2006 Jan; 12(2):563-8. PubMed ID: 16428501
[TBL] [Abstract][Full Text] [Related]
4. P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin.
Lin X; Ramamurthi K; Mishima M; Kondo A; Christen RD; Howell SB
Cancer Res; 2001 Feb; 61(4):1508-16. PubMed ID: 11245458
[TBL] [Abstract][Full Text] [Related]
5. [Study of bcl-2 antisense oligodeoxynucleotides on reversal of cisplatin resistance in ovarian cancer cell line A2780/DDP].
Li M; Yu LL; Cai LQ; Wang HB; Wang ZH; Wang ZH
Zhonghua Fu Chan Ke Za Zhi; 2006 Feb; 41(2):121-5. PubMed ID: 16640863
[TBL] [Abstract][Full Text] [Related]
6. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines.
Mamenta EL; Poma EE; Kaufmann WK; Delmastro DA; Grady HL; Chaney SG
Cancer Res; 1994 Jul; 54(13):3500-5. PubMed ID: 8012973
[TBL] [Abstract][Full Text] [Related]
7. Enhanced repair of a cisplatin-damaged reporter chloramphenicol-O-acetyltransferase gene and altered activities of DNA polymerases alpha and beta, and DNA ligase in cells of a human malignant glioma following in vivo cisplatin therapy.
Ali-Osman F; Berger MS; Rairkar A; Stein DE
J Cell Biochem; 1994 Jan; 54(1):11-9. PubMed ID: 8126081
[TBL] [Abstract][Full Text] [Related]
8. Cross-resistance between cisplatin and antimony in a human ovarian carcinoma cell line.
Naredi P; Heath DD; Enns RE; Howell SB
Cancer Res; 1994 Dec; 54(24):6464-8. PubMed ID: 7987844
[TBL] [Abstract][Full Text] [Related]
9. Analyses of ultraviolet-induced focus formation of hREV1 protein.
Murakumo Y; Mizutani S; Yamaguchi M; Ichihara M; Takahashi M
Genes Cells; 2006 Mar; 11(3):193-205. PubMed ID: 16483309
[TBL] [Abstract][Full Text] [Related]
10. [Mifepristone modulates glucosylceramide synthase expression and reverse multidrug resistance in ovarian cancer cells].
Liu Y; Wang LL
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(9):1727-30. PubMed ID: 18819906
[TBL] [Abstract][Full Text] [Related]
11. Electrochemotherapy with cisplatin in the treatment of tumor cells resistant to cisplatin.
Cemazar M; Sersa G; Miklavcic D
Anticancer Res; 1998; 18(6A):4463-6. PubMed ID: 9891510
[TBL] [Abstract][Full Text] [Related]
12. Single step selection of cis-diamminedichloroplatinum(II) resistant mutants from a human ovarian carcinoma cell line.
McLaughlin K; Stephens I; McMahon N; Brown R
Cancer Res; 1991 Apr; 51(8):2242-5. PubMed ID: 1901242
[TBL] [Abstract][Full Text] [Related]
13. [Suppression of insulin-like growth factor-1 receptor by RNA interference inhibits cell growth in vitro and induces chemosensitization of HO8910PM cell to cisplatin].
Gao H; Shi J; Ge SF; DI W
Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):45-9. PubMed ID: 18366933
[TBL] [Abstract][Full Text] [Related]
14. [Inhibitory effect of human mitochondria-targeted MPG recombinant on proliferation of human non-small cell lung cancer multidrug-resistant cell line A549/DDP].
Yu SC; Qian GS; Li YY; Lu WZ; Li J; Huang GJ
Ai Zheng; 2006 Apr; 25(4):421-6. PubMed ID: 16613673
[TBL] [Abstract][Full Text] [Related]
15. [Specific inhibition of HER-2 expression in ovarian carcinoma cells by siRNA targeting HER-2].
Lu YM; Zhang SL; Meng LR; Zhao YY
Zhonghua Yi Xue Za Zhi; 2006 Mar; 86(9):619-23. PubMed ID: 16681908
[TBL] [Abstract][Full Text] [Related]
16. Differential sensitization of human ovarian carcinoma and mouse L1210 cells to cisplatin and melphalan by glutathione depletion.
Andrews PA; Murphy MP; Howell SB
Mol Pharmacol; 1986 Dec; 30(6):643-50. PubMed ID: 3785141
[TBL] [Abstract][Full Text] [Related]
17. Synergism between dipyridamole and cisplatin in human ovarian carcinoma cells in vitro.
Jekunen A; Vick J; Sanga R; Chan TC; Howell SB
Cancer Res; 1992 Jul; 52(13):3566-71. PubMed ID: 1617625
[TBL] [Abstract][Full Text] [Related]
18. Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells.
Villedieu M; Louis MH; Dutoit S; Brotin E; Lincet H; Duigou F; Staedel C; Gauduchon P; Poulain L
Gynecol Oncol; 2007 Apr; 105(1):31-44. PubMed ID: 17275076
[TBL] [Abstract][Full Text] [Related]
19. Identification of genes whose expression is associated with cisplatin resistance in human ovarian carcinoma cells.
Cheng TC; Manorek G; Samimi G; Lin X; Berry CC; Howell SB
Cancer Chemother Pharmacol; 2006 Sep; 58(3):384-95. PubMed ID: 16404635
[TBL] [Abstract][Full Text] [Related]
20. [Expression of DNA transcription- and repair-related genes in cisplatin-resistant human ovarian carcinoma cell line COC1/DDP].
Cao MM; Zhang JR; Wang SM; Hu XG; Hu LJ
Di Yi Jun Yi Da Xue Xue Bao; 2005 Dec; 25(12):1478-81. PubMed ID: 16354609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
